Glomerulonephritis membranoproliferative – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Glomerulonephritis membranoproliferative – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Pegcetacoplan for Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-pegcetacoplan-for-patients-with-c3-glomerulopathy-or-immune-complex-membranoproliferative-glomerulonephritis/ Wed, 29 Apr 2026 14:58:04 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-pegcetacoplan-for-patients-with-c3-glomerulopathy-or-immune-complex-membranoproliferative-glomerulonephritis/ This clinical trial is focused on studying two kidney diseases: Complement 3 Glomerulopathy (C3G) and Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN). These are conditions where the immune system affects the kidneys, leading to problems with kidney function. The study is testing a treatment called Pegcetacoplan, which is given as a solution for infusion. This means the medication is delivered directly into the body through a needle. The study also involves a placebo, which is a substance with no active medication, to compare the effects of Pegcetacoplan.

The purpose of the study is to evaluate how effective and safe Pegcetacoplan is for patients with C3G or IC-MPGN. Participants in the study will receive the treatment twice a week. The study will last for a period of time, during which participants will be monitored to see if there is a reduction in proteinuria, which is the presence of excess protein in the urine and a sign of kidney damage. The study aims to see if Pegcetacoplan can help reduce this proteinuria and improve kidney function.

Throughout the study, participants will receive regular check-ups to monitor their health and the effects of the treatment. The study is designed to be double-blinded, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, to ensure unbiased results. The study will help determine if Pegcetacoplan can be a beneficial treatment option for those suffering from these specific kidney diseases.

]]> Study on the Safety and Effectiveness of Pegcetacoplan for Patients with Post-Transplant Recurrence of C3 Glomerulopathy or Immune Complex Membranoproliferative Nephritis https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-pegcetacoplan-for-patients-with-post-transplant-recurrence-of-c3-glomerulopathy-or-immune-complex-membranoproliferative-nephritis/ Wed, 29 Apr 2026 14:57:52 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-pegcetacoplan-for-patients-with-post-transplant-recurrence-of-c3-glomerulopathy-or-immune-complex-membranoproliferative-nephritis/ This clinical trial is focused on studying the treatment of two kidney diseases: Complement 3 Glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN). These conditions can occur after a kidney transplant and involve the immune system attacking the kidney, leading to damage. The treatment being tested is a medication called pegcetacoplan, which is given as a solution for infusion. This medication is designed to help improve the condition of the kidneys by targeting specific parts of the immune system.

The purpose of the study is to evaluate how effective pegcetacoplan is in improving the health of the kidneys affected by C3G or IC-MPGN. Participants in the study will receive pegcetacoplan through a subcutaneous injection, which means it is administered under the skin. The study will last for a period of 12 weeks, during which the effects of the treatment on the kidney condition will be closely monitored. An ambulatory syringe infusion system, known as the FreedomEdge® Syringe Infusion System, will be used to administer the medication.

Throughout the study, participants will undergo regular check-ups to assess the safety and effectiveness of the treatment. The main goal is to see if there is a reduction in the damage to the kidneys, as indicated by changes in specific markers in the kidney tissue. The study will also monitor other health indicators, such as kidney function and overall safety, to ensure that the treatment is both effective and safe for participants. The trial is open-label, meaning both the participants and the researchers know which treatment is being administered.

]]> Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN) https://clinicaltrials.eu/trial/study-on-the-effects-of-iptacopan-in-patients-with-idiopathic-membranoproliferative-glomerulonephritis-ic-mpgn/ Wed, 29 Apr 2026 14:26:57 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-iptacopan-in-patients-with-idiopathic-membranoproliferative-glomerulonephritis-ic-mpgn/ This clinical trial is focused on studying a kidney disease called Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN). This condition affects the kidneys and can lead to problems with kidney function. The study is testing a treatment called iptacopan, which is taken as a hard gelatin capsule. The purpose of the study is to see if iptacopan can help reduce the amount of protein in the urine, which is a sign of kidney damage, over a period of six months.

Participants in the study will be randomly assigned to receive either iptacopan or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will last for up to 12 months, with regular check-ups to monitor the participants’ health and the effects of the treatment.

Throughout the study, participants will have their kidney function and overall health closely monitored. This includes measuring the protein levels in their urine and checking their kidney function through blood tests. The study aims to provide valuable information about the safety and effectiveness of iptacopan in treating IC-MPGN, potentially offering a new treatment option for those affected by this kidney disease.

]]> Study on Long-term Safety and Efficacy of Pegcetacoplan for Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis https://clinicaltrials.eu/trial/study-on-long-term-safety-and-efficacy-of-pegcetacoplan-for-patients-with-c3-glomerulopathy-or-immune-complex-membranoproliferative-glomerulonephritis/ Wed, 29 Apr 2026 14:23:22 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-efficacy-of-pegcetacoplan-for-patients-with-c3-glomerulopathy-or-immune-complex-membranoproliferative-glomerulonephritis/ This clinical trial is focused on studying the long-term safety and effectiveness of a treatment called pegcetacoplan for patients with two specific kidney diseases: C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis. These conditions affect the kidneys and can lead to problems with kidney function. The study aims to understand how well pegcetacoplan works over an extended period and to ensure it is safe for patients to use.

Participants in this study will receive pegcetacoplan, which is administered as a subcutaneous infusion, meaning it is given under the skin using a special device. The study will monitor participants over time to see how their kidney function changes and to check for any side effects. The study will also compare the results to those from before the treatment started to see if there are improvements in kidney health.

Throughout the study, participants will be regularly assessed to track their progress and any changes in their condition. The study will last for several years, allowing researchers to gather comprehensive data on the long-term effects of pegcetacoplan. This information will help determine if pegcetacoplan is a viable long-term treatment option for these kidney diseases.

]]>